Leopoldo Ordine

Dr. Leopoldo Ordine

University Federico II, Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
FBFelice Borrelli
Felice Borrelli
Maria-Angela LosiMaria-Angela Losi
Maria-Angela Losi
GCGrazia Canciello
Grazia Canciello
GTGaetano Todde
Gaetano Todde
EPErrico Federico Perillo
Errico Federico Perillo
RLRaffaella Lombardi
Raffaella Lombardi
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiovascular disorder and is characterized by left ventricular hypertrophy (LVH), which is unexplained by abnormal loading conditions. HCM is inherited as an autosomal dominant trait and, in about 40% of patients, the causal mutation is identified in genes encoding sarcomere proteins. According to the results of genetic screening, HCM patients are currently categorized in two main sub-populations: sarcomeric-positive (Sarc+) patients, in whom the causal mutation is identified in a sarcomeric gene; and sarcomeric-negative (Sarc−) patients, in whom a causal mutation has not been identified. In rare cases, Sarc− HCM cases may be caused by pathogenic variants in non-sarcomeric genes. The aim of this review is to describe the differences in the phenotypic expression and clinical outcomes of Sarc+ and Sarc− HCM and to briefly discuss the current knowledge about HCM caused by rare non-sarcomeric mutations.

25 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
EPErrico Federico Perillo
Errico Federico Perillo
GCGrazia Canciello
Grazia Canciello
FBFelice Borrelli
Felice Borrelli
GTGaetano Todde
Gaetano Todde
MIMassimo Imbriaco
Massimo Imbriaco
Maria-Angela LosiMaria-Angela Losi
Maria-Angela Losi
Hypertrophic cardiomyopathy (HCM) is a genetic disease with heterogeneous clinical presentation and prognosis. Within the broad phenotypic expression of HCM, there is a subgroup of patients with a left ventricular (LV) apical aneurysm, which has an estimated prevalence between 2% and 5%. LV apical aneurysm is characterized by an area of apical dyskinesis or akinesis, often associated with regional scarring. To date, the most accepted pathomechanism of this complication is, in absence of coronary artery disease, the high systolic intra-aneurysmal pressure, which, combined with impaired diastolic perfusion from lower stroke volume, results in supply–demand ischemia and myocardial injury. Apical aneurysm is increasingly recognized as a poor prognostic marker; however, the efficacy of prophylactic anticoagulation and/or intracardiac cardioverted defibrillator (ICD) in improving morbidity and mortality is not yet clearly demonstrated. This review aims to elucidate the mechanism, diagnosis and clinical implication of LV aneurysm in patients with HCM.

Verified
Journal Article
Open access
PDF file
GCGrazia Canciello
Grazia Canciello
RLRaffaella Lombardi
Raffaella Lombardi
FBFelice Borrelli
Felice Borrelli
LOLeopoldo Ordine
Leopoldo Ordine
SCSuet Nee Chen
Suet Nee Chen
Maria-Angela LosiMaria-Angela Losi
Maria-Angela Losi
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by unexplained left ventricular hypertrophy (LVH), diastolic dysfunction, and increased sudden-death risk. Early detection of the phenotypic expression of the disease in genetic carriers without LVH (Gen+/Phen−) is crucial for emerging therapies. This clinical study aims to identify echocardiographic predictors of phenotypic development in Gen+/Phen−. Sixteen Gen+/Phen− (one subject with troponin T, six with myosin heavy chain-7, and nine with myosin-binding protein C3 mutations), represented the study population. At first and last visit we performed comprehensive 2D speckle-tracking strain echocardiography. During a follow-up of 8 ± 5 years, five carriers developed LVH (LVH+). At baseline, these patients were older than those who did not develop LVH (LVH−) (30 ± 8 vs. 15 ± 8 years, p = 0.005). LVH+ had reduced peak global strain rate during the isovolumic relaxation period (SRIVR) (0.28 ± 0.05 vs. 0.40 ± 0.11 1/s, p = 0.048) and lower global longitudinal strain (GLS) (−19.8 ± 0.4 vs. −22.3 ± 1.1%; p < 0.0001) than LVH- at baseline. SRIVR and GLS were not correlated with age (overall, p > 0.08). This is the first HCM study investigating subjects before they manifest clinically significant or relevant disease burden or symptomatology, comparing at baseline HCM Gen+/Phen− subjects who will develop LVH with those who will not. Furthermore, we identified highly sensitive, easily obtainable, age- and load-independent echocardiographic predictors of phenotype development in HCM gene carriers who may undergo early preventive treatment.

23 October 2024 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
LOLeopoldo Ordine
Leopoldo Ordine
Maria-Angela LosiMaria-Angela Losi
Maria-Angela Losi
GCGrazia Canciello
Grazia Canciello
FBFelice Borrelli
Felice Borrelli
GEGiovanni Esposito
Giovanni Esposito
Background: Orthostatic hypotension (OH) is a common cardiovascular disorder typically associated with autonomic dysfunction. However, various other mechanisms can contribute to its occurrence. Case summary: An 88-year-old woman was referred to the cardiology unit due to recurrent syncope episodes while standing. Echocardiography revealed a normally contracting left ventricle with severe hypertrophy, a restrictive filling pattern, reduced stroke volume, and a decreased inferior vena cava diameter (4 mm/m²). In the standing position, she experienced syncope, and invasive blood pressure monitoring confirmed OH, alongside a normal increase in heart rate and evidence of mid-left ventricular obstruction (MVO) on echocardiogram. Discontinuation of diuretics and administration of fluids and beta-blockers effectively resolved the OH. Discussion: This case underscores the importance of considering mechanisms beyond autonomic dysfunction and volume depletion in the aetiology of OH in elderly patients. Notably, this is the first documented case of OH associated with MVO occurring in an upright posture, resulting in a significant decrease in cardiac output and subsequent syncope. Preventing volume depletion and using non-vasodilating beta-blockers may represent optimal therapeutic strategies in such cases.

25 August 2025 in Diagnostics
Verified
Journal Article
Open access
GCGrazia Canciello
Grazia Canciello
STStefano Tozza
Stefano Tozza
LOLeopoldo Ordine
Leopoldo Ordine
BNBrigida Napolitano
Brigida Napolitano
GPGiovanni Palumbo
Giovanni Palumbo
Maria-Angela LosiMaria-Angela Losi
Maria-Angela Losi
Background: Hereditary transthyretin amyloidosis (ATTRv) is a rare, autosomal dominant multisystem disease caused by pathogenic variants in the transthyretin (TTR) gene. Although ATTRv is classically categorized into “cardiac” and “neurologic” phenotypes, recent evidence suggests a more complex and overlapping disease spectrum. Objectives: This study investigates the relationship between neurological staging and cardiac involvement through an integrated assessment of patients with confirmed TTR mutations. Methods and Results: Fifty-eight patients with genetically confirmed ATTRv (41% female, mean age 60 ± 15 years) were evaluated. Genotypes included Phe64Leu, Val30Met, Val122Ile, and others. Patients were stratified by neurological stage: G0 (asymptomatic carriers), G1 (symptomatic but ambulatory), and G2 (requiring walking support). Cardiac assessment included clinical evaluation, echocardiography with tissue Doppler, global longitudinal strain (GLS), and NT-proBNP levels. Cardiac markers worsened with neurological stage. NT-proBNP, left ventricular mass index, maximal wall thickness, and E/E′ ratio increased progressively, while GLS declined (G0: –19%, G1: –14%, G2: –13%; p < 0.001), indicating a progressive structural and functional myocardial disease. Ejection fraction remained preserved. Neurological stage independently predicted cardiac dysfunction after age adjustment. Conclusions: This is the first study to assess cardiac abnormalities across neurological stages in a well-characterized cohort of ATTRv patients. Cardiac involvement in ATTRv begins early, even in asymptomatic carriers, and progresses with neurological deterioration. GLS and diastolic parameters are sensitive indicators of early myocardial dysfunction, highlighting the need for integrated neurologic and cardiac monitoring in all patients with ATTRv, regardless of initial phenotype.

4 March 2026 in JACC: Case Reports
Verified
Journal Article
Open access
RPRoberto Polizzi
Roberto Polizzi
GCGrazia Canciello
Grazia Canciello
LOLeopoldo Ordine
Leopoldo Ordine
RLRaffaella Lombardi
Raffaella Lombardi
GEGiovanni Esposito
Giovanni Esposito
MLMaria Angela Losi
Maria Angela Losi
Myosin inhibitors represent a novel therapeutic strategy for obstructive hypertrophic cardiomyopathy (oHCM), directly targeting sarcomeric hypercontractility to reduce left ventricular outflow tract obstruction. Three patients with symptomatic oHCM enrolled in Italy's Early Access Program for mavacamten underwent 2D and 3D echocardiographic assessment at baseline and at 6 months. All experienced symptomatic improvement and left ventricular outflow tract obstruction reduction, accompanied by a modest decline in global left ventricular ejection fraction (LVEF) at 6 months follow-up. A 3-dimensional analysis revealed that LVEF reduction primarily involved mid and apical segments, while the basal function remained stable. These findings suggest that mavacamten selectively attenuates hypercontractility in relatively preserved myocardial regions rather than inducing global systolic dysfunction. Three-dimensional echocardiography provided novel insights into regional contractile adaptation, offering potential guidance for individualized dosing and monitoring. Mavacamten-induced LVEF decline reflects regional hypokinesia, not global dysfunction. Three-dimensional imaging enhances understanding of treatment response in oHCM.